Research Analysts Offer Predictions for FTH FY2026 Earnings

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) – Equities research analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Sensei Biotherapeutics in a research note issued on Wednesday, November 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($15.52) for the year, down from their prior forecast of ($13.54). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Sensei Biotherapeutics’ current full-year earnings is ($13.35) per share. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q4 2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.90) EPS, Q4 2027 earnings at ($0.97) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($3.10) EPS and FY2030 earnings at ($3.09) EPS.

Several other brokerages have also commented on FTH. Needham & Company LLC initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price target on the stock. Guggenheim reduced their price objective on Sensei Biotherapeutics from $70.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. JonesTrading assumed coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price objective for the company. Citigroup raised their target price on Sensei Biotherapeutics from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.58.

Sensei Biotherapeutics Trading Down 20.2%

NASDAQ FTH opened at $10.65 on Friday. Sensei Biotherapeutics has a 52 week low of $7.45 and a 52 week high of $42.14. The company has a market cap of $275.20 million, a PE ratio of -0.08 and a beta of -0.15. The stock has a 50-day moving average price of $25.65.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.13).

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the 1st quarter valued at about $22,758,000. Candriam S.C.A. bought a new stake in shares of Sensei Biotherapeutics during the 3rd quarter worth about $9,542,000. State Street Corp bought a new stake in shares of Sensei Biotherapeutics during the 3rd quarter worth about $9,262,000. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics in the 2nd quarter worth approximately $3,610,000. Finally, Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Institutional investors own 10.50% of the company’s stock.

Key Stories Impacting Sensei Biotherapeutics

Here are a few of the latest stories about FTH:

• Neutral Sentiment: HC Wainwright maintained its Buy rating and $60 price target despite revising estimates lower. MarketBeat report
• Neutral Sentiment: A separate announcement under the name Faeth Therapeutics (Nasdaq: FTH) said management would attend November investor conferences; it may provide investor exposure, but the announcement gave no new business or clinical update. Conference announcement
• Negative Sentiment: HC Wainwright lowered its projected losses for Q4 2026 and each quarter of 2027, as well as its full-year estimates for 2026–2030. For example, its FY2027 EPS estimate moved to a loss of $3.60 from $2.68, and its FY2026 estimate to a loss of $15.52 from $13.54. The broader revisions point to weaker expected earnings and may weigh on the stock. MarketBeat analyst estimates

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.